Andrew Tsai
Stock Analyst at Jefferies
(1.72)
# 3,390
Out of 5,090 analysts
27
Total ratings
36.36%
Success rate
-9.14%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $18.23 | +75.53% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $13.38 | +86.85% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.36 | -6.35% | 1 | Oct 22, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $300 | $191.83 | +56.39% | 1 | Oct 16, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $75 → $56 | $54.59 | +2.59% | 1 | Oct 9, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $181.82 | +4.50% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $22.81 | +53.44% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $30.96 | -3.10% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $74.74 | -6.34% | 1 | Jul 14, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.42 | -26.79% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $148.41 | +34.76% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $16.80 | +60.71% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $3.96 | +228.28% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $28.74 | +21.78% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $4.29 | +249.65% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.42 | +111.27% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $3.87 | +675.19% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $4.39 | +515.03% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $44.69 | -48.53% | 1 | Jun 1, 2020 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $18.23
Upside: +75.53%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $13.38
Upside: +86.85%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.36
Upside: -6.35%
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $65 → $300
Current: $191.83
Upside: +56.39%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $75 → $56
Current: $54.59
Upside: +2.59%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $181.82
Upside: +4.50%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $22.81
Upside: +53.44%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $30.96
Upside: -3.10%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $74.74
Upside: -6.34%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.42
Upside: -26.79%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $148.41
Upside: +34.76%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $16.80
Upside: +60.71%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $3.96
Upside: +228.28%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $28.74
Upside: +21.78%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $4.29
Upside: +249.65%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.42
Upside: +111.27%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $3.87
Upside: +675.19%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $4.39
Upside: +515.03%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $44.69
Upside: -48.53%